Last reviewed · How we verify

NCT07181070

The Use of Indocyanine Green Fluorescence (ICG) During Laparoscopic Heller- Dor

Recruiting now Last updated 23 September 2025
What this trial tests

trial in Achalasia, Esophageal in 70 participants. Currently enrolling.

Timeline
1 November 2022
Primary endpoint
31 October 2025
31 October 2026

Quick facts

Lead sponsorFederico II University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment70
Start date1 November 2022
Primary completion31 October 2025
Estimated completion31 October 2026
Sites1 location across Italy

Conditions studied

Sponsor

Federico II University

Who can join

18 and older, any sex, with Achalasia, Esophageal or Achalasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim this prospective observational study is to evaluate the role of Indocyanine Green Fluorescence (ICG) in patients with achalasia underwent to Heller-Dor laparoscopic. The main gol are: * If with use of ICG iatrogenic mucosal leaks can be identified and, if necessary, improve the myotomy. * Assess the need for postoperative radiographic control using esophagogastric radiography with gastrografin. * Compare clinical characteristics, perioperative outcomes, and 12-month postoperative follow-up between the two populations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Achalasia, Esophageal

Currently open trials in the same condition.

Other Federico II University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07181070.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing